Bluebird, Vertex Gene Therapies May Answer $1m Question: Can Competition Reduce Rx Prices?

Medicaid is expected to be the primary payer for the sickle cell treatments. Bluebird bio maintains outcomes-based arrangements are a key part of its access strategy and will overcome what appears to be a significant competitive disadvantage on price compared to the Vertex product.